𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia

✍ Scribed by Kanellopoulou, Theoni; Alexopoulou, Alexandra

Book ID
121284542
Publisher
Informa plc
Year
2013
Tongue
English
Weight
360 KB
Volume
13
Category
Article
ISSN
5847-4714

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The effect of bevacizumab (Avastin) trea
The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia
✍ Jana Simonds; Frank Miller; Jess Mandel; Terence M. Davidson πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 83 KB

## Abstract ## Objectives/Hypothesis: Determine the effectiveness of treating epistaxis in hereditary hemorrhagic telangiectasia (HHT) with potassium titanyl phosphate (KTP) laser cautery combined with submucosal injection of 100 mg of bevacizumab. ## Study Design: Retrospective pilot study. ##

Bevacizumab reverses need for liver tran
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
✍ Andrew Mitchell; Leon A. Adams; Gerry MacQuillan; Jon Tibballs; Rohan vanden Dri πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 153 KB

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high-output cardiac failure. Liver transplantation is indica